Quarterly operating income at Swiss drugmaker Novartis slipped as competition weighed on prescriptions of multiple sclerosis drug Gilenya.For Novartis, which reports results in dollars, a strong U.S. ...
Source LinkQuarterly operating income at Swiss drugmaker Novartis slipped as competition weighed on prescriptions of multiple sclerosis drug Gilenya.For Novartis, which reports results in dollars, a strong U.S. ...
Source Link
Comments